---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-000991"
form_type: "8-K"
ticker: "DYN"
cik: "0001818794"
company_name: "Dyne Therapeutics, Inc."
filed_at: "2024-01-03T23:59:59+00:00"
generated_at: "2026-06-07T04:47:10.196549+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Dyne Therapeutics announces positive initial clinical data from ACHIEVE and DELIVER trials

## Summary
- DYNE-101 in ACHIEVE trial: 19% mean splicing correction at 3.4 mg/kg at 3 months; 3.8 sec myotonia benefit at 1.8 mg/kg at 6 months.
- DYNE-251 in DELIVER trial: 0.88% mean dystrophin expression at 5 mg/kg at 6 months, exceeding eteplirsen with 24-fold lower dose.
- Favorable safety profiles: no related serious adverse events; dose escalation to 6.8 mg/kg (ACHIEVE) and 40 mg/kg (DELIVER) supported.
- Company plans to initiate registrational cohorts for both programs by end of 2024, with next data updates in second half of 2024.

## SEC filing metadata
- accession: 0001193125-24-000991
- form_type: 8-K
- ticker: DYN
- cik: 0001818794
- company_name: Dyne Therapeutics, Inc.
- filed_at: 2024-01-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818794/000119312524000991/0001193125-24-000991-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818794/000119312524000991/d586587d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-000991
- JSON: https://secwatch.observer/filing/0001193125-24-000991.json
- Plain text: https://secwatch.observer/filing/0001193125-24-000991.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.